NMD Pharma

We are excited to be participating in Synapse DK - Life Science Connect’s half-day event at INCUBA A/S Skejby, Aarhus, taking place on 20 March. This event will provide #LifesSciences students with the chance to connect with industry professionals from innovative companies, expand their networks and provide inspiration on the multitude of #career opportunities within the growing Danish #biotech environment. Come and find us to discuss potential careers at #NMDPharma. Throughout the day, you will meet our Research Scientists, Michael Voldsgaard Clausen, Kamilla Løhde Tordrup Dybdahl, Henriette Tobiesen and Head of Biological Research Martin Broch-Lips. They are looking forward to meeting you and having a great conversation! Register for the event here: https://lnkd.in/dtusJPrJ  #Innovation #NeuromuscularDisease #Event #Recruitment 

NMD Pharma is pleased to be sponsoring another Cure SMA Summit of Strength meeting in Philadelphia, PA, on Saturday, 15 March. The meeting will bring together local and national experts with extensive experience in spinal muscular atrophy (#SMA) as NMD Pharma progresses, NMD670, our skeletal muscle-activating therapy for the treatment of severe neuromuscular disorders, currently being evaluated in an ongoing Phase 2 clinical study in adults with SMA, which is actively recruiting (for information on this trial follow this link). Mila Woodfield will be representing NMD Pharma at our booth, with information on our ongoing #ClinicalTrial, and will give a short presentation about the Company and our progress to date. We look forward to meeting all members of the SMA community in Philadelphia! For more about the event: https://lnkd.in/dkyKW-5v Discover more about our work here: https://www.nmdpharma.com/ #NMDPharma #Innovation #SpinalMuscularAtrophy #CureSMA

Today is International Women’s Day, a day to celebrate the value that women bring to our business and the wider #biotech community, as well as recognise the importance of #diversity and #inclusion across all parts of society. As we continue to pursue our vision, a future in which patients with #NeuromuscularDisease live better and more independent lives, we recognise that diversity and inclusion brings a wider range of perspectives, leading to improved decision-making, increased creativity, better problem-solving, an increased understanding of patient needs, and ultimately greater innovation in developing therapies of value. Join us in celebrating the incredible women at NMD Pharma and beyond, whose contributions continue to inspire and drive #innovation here at NMD Pharma and elsewhere. Learn more: https://lnkd.in/dPa6RXf #NMDPharma #IWD2025 #AccelerateAction #IWD

Our scientists will be presenting four posters on our skeletal muscle specific chloride ion channel (ClC-1) inhibitors for neuromuscular diseases at the upcoming Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas, USA from 16-19 March. Jeanette Jeppesen Morgen, Nete Huus, Vera K. and Martin Brandhøj Skov, our Innovation Manager will also be giving an oral presentation on the positive effects of our orally bioavailable small molecule ClC-1 inhibitor in a muscle-specific kinase Myasthenia Gravis (#MG) rat model to improve disease symptoms. A full team of NMD Pharma Scientists, Clinicians and Leadership Team, including CEO/Founder Thomas Holm Pedersen will be at the Conference, discussion progress with our skeletal muscle targeted ClC-1 ion channel inhibitors at the abstract sessions and throughout the meeting. Find the full conference agenda here: https://lnkd.in/dhuVwFGj #MDAConference #NMDPharma #Biotech #Innovation #Neuromuscular #RareDisease #ScientificResearch 

Today – the last day of February – is #RareDiseaseDay, a day to raise awareness and generate change for the 300 million individuals and their families affected by rare diseases globally. At #NMDPharma, we are Passionate about Movement, working alongside and learning from scientific and patient communities to transform science into novel therapies with the potential to enable those living with neuromuscular diseases to live better, more independent lives. Since our founding as a biopharma company in 2015, Rare Disease Day has provided us with an essential opportunity to shine a spotlight on the almost 7,000 #RareDiseases, including spinal muscular atrophy (#SMA), myasthenia gravis (#MG), and Charcot-Marie-Tooth disease (#CMT). Over the years, we have lit up our offices in the colours of Rare Disease Day to spread awareness locally in Aarhus, held fundraisers, and have had the pleasure of hosting rare disease patients and representatives from several international and local rare #NeuromuscularDisease patient advocacy groups at our headquarters, which provided valuable insight into specific patient needs. Join us in raising awareness of rare diseases, not just today, but every day. #Innovation #LightUpForRare #MyastheniaGravis #SpinalMuscularAtrophy #CharcotMarieTooth

Dan Brennan from NMD Pharma, will be at the Cure SMA Charlotte Summit of Strength this Saturday, 1 March to talk about NMD Pharma’s skeletal muscle-targeted drug therapy in development for rare neuromuscular diseases. If you would like to know more about our ongoing Phase 2b clinical trial for adults with Type 3 SMA please reach out to us at contact@nmdpharma.com, or meet Dan in North Carolina this Saturday at the Summit of Strength meeting! Register for the event here: https://lnkd.in/d7kaQd4H #Conference #CureSMA #SpinalMuscularAtrophy #Innovation #Biotech #NMDPharma #SummitofStrength 

In recognition of #RareDiseaseDay, we are sharing a recent interview that our team conducted with Dr. Albert Freedman, founder of Rare Counseling, an independent practice that supports patients and families affected by #RareDiseases, disabilities and medically complex conditions. Dr. Freedman’s approach, which was shaped by his experience with his son Jack, who lived with spinal muscular atrophy (#SMA) for 26 years, is focused on supporting the unique emotional needs of individuals and families affected by rare disease and disability, as well as the evolving and dynamic needs of these communities. Many thanks to Dr. Freedman for sharing his perspective and work. We have learned so much from discussions and interactions with him.   For more on Dr. Freedman’s journey with SMA and how it has shaped his work and his thoughts on recent medical and regulatory progress in the rare disease space, watch the full interview here: https://lnkd.in/dvMe8FCW #NMDPharma #Innovation #NeuromuscularDisease #RareDisease #SpinalMuscularAtrophy

We are proud to have contributed to the Lundbeckfonden / Lundbeck Foundation and Heidrick & Struggles ‘Fit for Future Growth’ pilot published last week. The program, a tailored programme aimed at helping early-stage biotech companies, builds value through increased awareness of the benefits and challenges of working with #diversity. Our NMD Pharma #ESG Lead, Chloe Arrowsmith Jensen, participated in a short series of focused in-person workshops, to help produce a best practice manual for #recruitment and building successful teams. At NMD Pharma, we recognise that there is value in attracting and maintaining a diverse and inclusive workforce to bring different perspectives and mindsets into decision making processes in our commitment to improving muscle strength, power and endurance for patients impacted by neuromuscular diseases. #NMDPharma #NeuromuscularDisease #CSR #Responsibility #FitforFutureGrowth

In anticipation of #RareDiseaseDay2025 on 28 February, we wanted to “muscle in” to generate awareness to this important rare-disease-community-led global event and provide some interesting insights about rare neuromuscular diseases! This year's Rare Disease Day emphasizes the need for equal access to diagnosis, treatment, and care for all rare disease patients, learn more about equitable access to healthcare here: https://lnkd.in/gk6hbAF At NMD Pharma we are committed to advancing treatments for people suffering from rare neuromuscular diseases and are conducting several clinical trials for adults with spinal muscular atrophy (#SMA), generalized myasthenia gravis (#gMG), and Charcot-Marie-Tooth disease (#CMT).  Please reach out to contact@nmdpharma.com for more information on our clinical studies and company. #NMDPharma #Biotech #Innovation #NeuromuscularDisease #RareDisease

NMD Pharma is #hiring! As we continue to grow, we are looking for a Business Controller to join our Finance team at our global headquarters in Aarhus, Denmark. In this role, you will have unique opportunities to explore and learn more about different areas of #finance and #businesscontrolling. Whether you have a few or several years of experience is not important, what is more important is your mindset, and that you want to grow with us. Your next step with NMD Pharma we promise will be fun, challenging, and you play a part in shaping it! To find out more about this #JobOpportunity and to apply: https://lnkd.in/dteiqjtF #NMDPharma #NeuromuscularDisease #Biotech #Innovation #Financejobs #Businesscontrollerjob #JobOpening #NowHiring